Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception

      Abstract

      Initially approved for use in the United States nearly 50 years ago, oral hormonal contraceptives containing both estrogen and progestin have undergone steady improvements in safety and convenience. Concurrent with improvements in safety associated with decreasing doses of both steroids, there has been an increased incidence of unscheduled bleeding and spotting. There exist no standards regarding data collection techniques and methods, and reporting and analysis of bleeding and spotting events during combined hormonal contraceptive (CHC) trials. For the regulatory review of hormonal contraceptives, data regarding the incidence of bleeding and spotting events are not included in either of the traditional categories of efficacy and safety. Standardization of methods for collecting and analyzing data about cycle control in all clinical trials of CHCs is long overdue. Until such standards are developed and implemented, clinicians need to familiarize themselves with the techniques used in each study in order to provide correct information to their patients about the frequency of bleeding and spotting associated with different formulations and delivery systems.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Asbell B.
        Pill kills! The pill. A biography of the drug that changed the world. Random House, New York1995: 301-312
        • Goldzieher J.W.
        • Moses L.E.
        • Averkin E.
        • et al.
        A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives.
        Fertil Steril. 1971; 22: 609-623
        • Dionne P.
        • Vickerson F.
        A double-blind comparison of two oral contraceptive vs. containing 50 ��g and 30 ��g ethinyl estradiol.
        Curr Ther Res. 1974; 16: 281-288
        • Snider S.
        The pill: 30 years of safety concerns.
        (Accessed on February 6, 2006)
        • Belsey E.M.
        • Carlson N.
        The description of menstrual bleeding patterns: towards fewer measures.
        Stat Med. 1991; 19: 267-284
        • Anderson F.D.
        • Halt H.
        • The Seasonale-301 Study Group
        A multicenter, randomized study of an extended cycle oral contraceptive.
        Contraception. 2003; 68: 89-96
        • Belsey E.M.
        • Machin D.
        • d'Arcangues C.
        The analysis of vaginal bleeding patterns induced by fertility regulating methods.
        Contraception. 1986; 34: 253-260
        • Archer D.F.
        • Maheux R.
        • DelConte A.
        • O'Brien F.
        • North American Levonorgestrel Study Group (NALSG)
        Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 ��g levonorgestrel and 10 ��g ethinyl estradiol (Alesse��).
        Am J Obstet Gynecol. 1999; 181: S39-S44
        • Audet M.-C.
        • Moreau M.
        • Koltun W.D.
        • et al.
        Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive.
        JAMA. 2001; 285: 2347-2354
        • Hampton R.M.
        • Short M.
        • Beiber E.
        • et al.
        Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin FE 1/20.
        Contraception. 2001; 63: 289-295
        • The Mircette Study Group
        An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen���progestin oral contraceptive.
        Am J Obstet Gynecol. 1998; 179: S2-S8
        • Parsey K.S.
        • Pong A.
        An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
        Contraception. 2000; 61: 105-111
        • Zieman M.
        • Guillebaud J.
        • Weisberg E.
        • Shangold G.A.
        • Fisher A.L.
        • Creasy G.W.
        Contraceptive efficacy and cycle control with the Ortho Evra���/Evra��� transdermal system: the analysis of pooled data.
        Fertil Steril. 2002; 77: S13-S18
        • Stone A.A.
        • Shiffman S.
        • Schwartz J.E.
        • et al.
        Patient compliance with paper and electronic diaries.
        Control Clin Trials. 2003; 24: 182-199
        • Raymond S.T.
        • Ross R.N.
        Electronic subject diaries in clinical trials.
        Appl Clin Trials. 2000; : 3-8
        • Belsey E.H.
        • Task Force on Long-Acting Systemic Agents for Fertility Regulation
        Determinants of menstrual bleeding patterns among women using natural and hormone methods of contraception: I. Regional variation.
        Contraception. 1988; 38: 227-243
        • Belsey E.M.
        • Task Force on Long-Acting Systemic Agents for Fertility Regulation
        Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception.
        Contraception. 1988; 38: 181-206
        • Belsey E.M.
        • Farley T.M.M.
        The analysis of menstrual bleeding patterns: a review.
        Contraception. 1988; 38: 129-156
        • Westhoff C.
        • Morroni C.
        • Kerns J.
        • Murphy P.A.
        Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial.
        Fertil Steril. 2003; 79: 322-329
      1. Mircette�� Medical Review(s). Center for Drug Evaluation and Research Application No. NDA 20-713.